MARK SCHINDEL

Mark Schindel joined Boomerang Ventures as an Executive in Residence (XiR), bringing 25+ years of experience spanning environmental, human and animal health industries, having held leadership positions, including C-level and Board roles in start-ups through larger corporations.

Mark has broad international experience in the medical device (Biomet, Zimmer, Tornier), pharmaceutical/biotech (Roche), life-science (Vanderbilt University Tech Transfer) and Government (US DOE/Battelle) sectors. Mark’s expertise spans marketing, sales, brand/product management, project management, R&D, clinical, and business development (M&A, licensing). Specific to medical devices, Mark has worked across craniomaxillofacial, pediatrics, plastic surgery, cardiothoracic/cardiovascular, hips, knees, shoulders, foot and ankle and regenerative medicine. Products have ranged from pre-operative technologies to implants (including biologics, synthetics and xenografts) and delivery technologies (robotics, patient-specific instruments, computer-assisted surgery, injectables, disposables, etc.).

As an entrepreneur, Mark served as CEO, Co-founder, and Board Member for Owl Manor Medical, LLC, an animal health biologics/medical device company with a focused regenerative medicine portfolio targeting equine and companion animal joint and soft tissue preservation. Following a successful Series A financing round, Owl Manor grew in revenues and profitability through its globally recognized portfolio. In addition to building a direct U.S./Canada sales channel, Owl Manor established a successful international business through a combination of distribution and direct sales across Europe, the Middle East, Australia, and Mexico. Founded in February 2015, Owl Manor was acquired on June 1, 2021, by Zoetis, the World’s Largest Animal Health company.

Mark holds an MBA from Vanderbilt University and a B.S. with honors from Purdue University.